WELLESLEY, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held virtually February 11-12, 2025.
Oppenheimer 35th Annual Healthcare Life Sciences Conference
Format: Presentation and one-on-one investor meetings
Date: February 12, 2025
Time: 9:20 a.m. ET
Webcast: Click here
About Climb Bio, Inc.
Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy. For more information, please visit climbbio.com.
Investors
Chris Brinzey
ICR Healthcare
This email address is being protected from spambots. You need JavaScript enabled to view it.
339-970-2843
Media
Jon Yu
ICR Healthcare
This email address is being protected from spambots. You need JavaScript enabled to view it.
475-395-5375
| Last Trade: | US$3.01 |
| Daily Volume: | 0 |
March 25, 2025 February 25, 2025 February 24, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
